Leerink Partnrs Analysts Lower Earnings Estimates for EW

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Leerink Partnrs reduced their Q4 2025 earnings per share estimates for shares of Edwards Lifesciences in a report released on Thursday, April 24th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will earn $0.63 per share for the quarter, down from their previous estimate of $0.64. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' FY2028 earnings at $3.68 EPS and FY2029 earnings at $4.14 EPS.

EW has been the subject of a number of other research reports. Barclays boosted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Robert W. Baird upped their price target on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a research report on Friday, April 25th. Evercore ISI decreased their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded up $0.80 during trading hours on Monday, reaching $75.98. The company's stock had a trading volume of 705,193 shares, compared to its average volume of 4,996,551. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences has a one year low of $58.93 and a one year high of $95.25. The company's 50 day simple moving average is $71.08 and its 200 day simple moving average is $71.26. The stock has a market cap of $44.67 billion, a P/E ratio of 10.91, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the company earned $0.66 earnings per share. Edwards Lifesciences's quarterly revenue was up 6.2% on a year-over-year basis.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Edwards Lifesciences by 5.3% during the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after buying an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after buying an additional 126,194 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock worth $723,664,000 after buying an additional 696,965 shares during the last quarter. Finally, Norges Bank bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $610,895,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.